<table id="_Reftable16" width="80%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 16	Amino Acid Substitutions in Viremic Subjects Across HBV Trials of VIREAD</caption>
<col width="18%"></col>
<col width="18%"></col>
<col width="18%"></col>
<col width="18%"></col>
<col width="19%"></col>
<thead>
<tr>
<th align="left" stylecode="Rrule Toprule " valign="top"></th>
<th align="left" colspan="3" stylecode="Rrule Botrule Toprule " valign="top">
<content stylecode="bold">Compensated Liver Disease</content>
</th>
<th align="left" rowspan="2" stylecode="Toprule " valign="top">
<content stylecode="bold">Decompensated Liver Disease  (N=39)</content>
<footnote id="_Reftable16d">Subjects with decompensated liver disease from Study 0108 (N=39) receiving up to 48 weeks of treatment with VIREAD.</footnote>
</th>
</tr>
<tr>
<th align="left" stylecode="Rrule Botrule " valign="top"></th>
<th align="left" stylecode="Rrule Botrule " valign="top">
<content stylecode="bold">Nucleotide-Naïve      (N=417)</content>
<footnote id="_RefID0EM3BI">Nucleotide-naïve subjects from Studies 0102 (N=246) and 0103 (N=171) receiving up to 240 weeks of treatment with VIREAD.</footnote>
</th>
<th align="left" stylecode="Rrule Botrule " valign="top">
<content stylecode="bold">HEPSERA-Experienced (N=247)</content>
<footnote id="_RefID0EQ3BI">HEPSERA-experienced subjects from Studies 0102/0103 (N=195) and 0106 (N=52) receiving up to 192 weeks of treatment with VIREAD after switching to VIREAD from HEPSERA. Study 0106, a randomized, double-blind, 168-week Phase 2 trial, has been completed.</footnote>
</th>
<th align="left" stylecode="Rrule Botrule " valign="top">
<content stylecode="bold">Lamivudine- Resistant (N=136)</content>
<footnote id="_Reftable16c">Lamivudine-resistant subjects from Study 0121 (N=136) receiving up to 96 weeks of treatment with VIREAD after switching to VIREAD from lamivudine.</footnote>
</th>
</tr>
</thead>
<tbody>
<tr>
<td stylecode="Rrule Toprule Botrule ">
<paragraph>Viremic at Last Time Point on VIREAD</paragraph>
</td>
<td stylecode="Rrule Toprule Botrule " valign="middle">
<paragraph>35/417 (8%)</paragraph>
</td>
<td stylecode="Rrule Toprule Botrule " valign="middle">
<paragraph>34/247 (14%)</paragraph>
</td>
<td stylecode="Rrule Toprule Botrule " valign="middle">
<paragraph>9/136 (7%)</paragraph>
</td>
<td stylecode="Toprule Botrule " valign="middle">
<paragraph>7/39 (18%)</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Botrule ">
<paragraph>Treatment-Emergent Amino Acid Substitutions<footnote id="_RefID0EK4BI">Denominator includes those subjects who were viremic at last time point on VIREAD monotherapy and had evaluable paired genotypic data.</footnote>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="middle">
<paragraph>19<footnote id="_RefID0EP4BI">Of the 19 subjects with treatment-emergent amino acid substitutions during Studies 0102 and 0103, 5 subjects had substitutions at conserved sites and 14 subjects had substitutions only at polymorphic sites, and 8 subjects had only transient substitutions that were not detected at the last time point on VIREAD.</footnote>/33 (58%)</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="middle">
<paragraph>10<footnote id="_RefID0EV4BI">Of the 10 HEPSERA-experienced subjects with treatment-emergent amino acid substitutions, 2 subjects had substitutions at conserved sites and 8 had substitutions only at polymorphic sites.</footnote>/27 (37%)</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="middle">
<paragraph>6<footnote id="_Reftable16h">Of the 6 lamivudine-resistant subjects with treatment-emergent substitutions during Study 0121, 3 subjects had substitutions at conserved sites and 3 had substitutions only at polymorphic sites.</footnote>/8 (75%)</paragraph>
</td>
<td stylecode="Botrule " valign="middle">
<paragraph>3/5 (60%)</paragraph>
</td>
</tr>
</tbody>
</table>